Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | June 3, 2008 | ||||
Last Updated Date | December 2, 2008 | ||||
Start Date † | April 2008 | ||||
Current Primary Outcome Measures † |
|
||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00691353 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
To depict sociodemographic characteristics and comorbidities. [ Time Frame: Reported at the site visit ] | ||||
Original Secondary Outcome Measures † | Same as current | ||||
Descriptive Information | |||||
Brief Title † | Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers | ||||
Official Title † | Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers | ||||
Brief Summary | Cross - Sectional study requiring one visit at the investigators office for the data collection.
|
||||
Detailed Description | |||||
Study Phase | |||||
Study Type † | Observational | ||||
Study Design † | Case-Only, Cross-Sectional | ||||
Condition † | Bipolar Disorder | ||||
Intervention † | |||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Completed | ||||
Estimated Enrollment † | 540 | ||||
Completion Date | July 2008 | ||||
Primary Completion Date | July 2008 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 65 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | Greece | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00691353 | ||||
Responsible Party | Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director, AstraZeneca, SA Greece | ||||
Secondary IDs †† | |||||
Study Sponsor † | AstraZeneca | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | AstraZeneca | ||||
Verification Date | December 2008 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |